久久久无码人妻精品无码_6080YYY午夜理论片中无码_性无码专区_无码人妻品一区二区三区精99

WORLD> Global General
World's largest malaria vaccine trial underway in Africa
(Xinhua)
Updated: 2009-11-04 16:24

NAIROBI: A pivotal efficacy trial of RTS,S, the world's most clinically advanced malaria vaccine candidate, is now underway in seven African countries.

The trial, which is expected to involve up to 16,000 children, is on schedule, with more than 5,000 children already enrolled, researchers announced late Tuesday at the 5th Multilateral Initiative on Malaria Pan-African Malaria Conference underway in Nairobi.  

The trial is underway in Burkina Faso, Gabon, Ghana, Kenya, Malawi, Mozambique and Tanzania.

Related readings:
World's largest malaria vaccine trial underway in Africa Mosquitoes deliver malaria 'vaccine' through bites
World's largest malaria vaccine trial underway in Africa Millions die because of high malaria drug prices
World's largest malaria vaccine trial underway in Africa African leaders ally to eradicate deadly malaria
World's largest malaria vaccine trial underway in Africa New approach could stop 6 million African malaria cases

The health experts were optimistic that the malaria vaccine could be made available to African governments by the year 2012.

Sirima Sodiomon of the National Centre for Research and Malaria Training in Burkina Faso said that the vaccine targeted the African continent because it was the most prone to the Malaria epidemic.

He said the efficacy rate of the vaccine was expected to be about 30-50 percent. "We need to continue with the research and may be the second generation vaccine which may come up in five to six years may have a higher efficacy rate of about 80-90 percent," Sodiomon said.

He said researchers were now on the third phase of trials which was the most crucial and involved large number of people for the clinical tests and this would have 16,000 children, 5,000 of whom would be from Kenya.

"Vaccines are one of the best ways to protect against any disease but currently we don't have any efficacy vaccine but at least we hope to have this one which will protect from 30-50 percent and then compliment it with other strategies like bed nets, " the medic said.

GlaxoSmithKline Biologicals' (GSK Bio) RTS,S is the first malaria vaccine candidate to demonstrate significant efficacy during early development to warrant Phase III testing.    

It is the leading vaccine candidate in the global effort by the PATH Malaria Vaccine Initiative (MVI) to develop a malaria vaccine.

"A malaria vaccine could help save countless lives and redefine the future for Africa's children," said Dr. Patricia Njuguna, RTS, S principal investigator (KEMRI-Wellcome Trust, Kilifi, Kenya) and chair of the Clinical Trials Partnership Committee, a collaboration of African research institutions, MVI, and GSK Bio that is leading the clinical development of RTS,S.

"Communities all across Africa are dedicated to this future and are participating to ensure that we develop a vaccine with an acceptable safety and efficacy profile."

RTS,S is the first vaccine designed primarily for use in Africa, where malaria kills more than 800,000 people every year, the majority of them children under the age of five.

By conducting the trial in seven different countries across Sub-Saharan Africa, researchers will be able to evaluate the vaccine candidate's efficacy in a variety of settings, with diverse patterns of malaria transmission.

For example, some trial sites are located in areas where there is a year-round threat of malaria, while others experience only seasonal transmission.

All of the research centers were chosen for their track record of world-class clinical research, strong community relations and commitment to meeting the highest international ethical, medical, clinical and regulatory standards.

"This is a tremendous moment in the fight against malaria and the culmination of more than two decades of research, including 10 years of clinical trials in Africa," said Joe Cohen, co-inventor of RTS,S and Vice President of R&D, Vaccines for Emerging Diseases and HIV, at GSK Biologicals.

"The Phase III trial is a huge undertaking that depends on effective coordination between researchers, regulators, families and communities. Everyone involved has invested significant energy and resources to pave the way for what could become the world's first malaria vaccine."

Recent Phase II studies showed that RTS,S reduced clinical episodes of malaria by 53 percent over an eight-month follow-up period.

Findings from a Phase II trial initiated in 2002 and conducted with more than 2,000 children in southern Mozambique, published in the medical journal The Lancet in 2004 and 2005, showed that RTS,S was efficacious for at least 18 months in reducing clinical malaria by 35 percent, and severe malaria by 49 percent.

In addition, RTS,S was shown to have a promising safety and tolerability profile when used alongside the World Health Organization's (WHO) standard infant vaccines.

"This historic trial could lead to the availability of a vaccine with the potential to save the lives of hundreds of thousands of African children, if the data are positive," said Dr. Christian Loucq, director of the PATH Malaria Vaccine Initiative.

"But development is only half the mission; MVI and its partners are committed to ensuring this vaccine reaches those who need it most. We hope the international community will respond by starting to prepare for the day when -- if all goes well -- this vaccine will be available for distribution and use."

The Phase III trial will evaluate the vaccine's efficacy in two groups of children. One group, aged 6 to 12 weeks, will be vaccinated as part of their regular schedule of infant immunizations; the second group includes children aged 5 to 17 months.

The vaccine profile is intended primarily for infants, as they and children under the age of five are the most vulnerable to malaria.

"This is the largest trial ever conducted in Africa of a vaccine specifically designed for use with African children. We have great appreciation for the families and children participating," said Dr. Salim Abdulla, director of the Ifakara Health Institute, Tanzania, which is participating in the Phase III trial.

"Development of RTS,S across Africa has strengthened our research capacity, a legacy that will far outlast the trials."

Each country hosting a study site has undertaken independent reviews to ensure the trial meets national safety, ethical and legal standards for medical research.

In addition, an independent data and safety monitoring board oversees the entire trial with support from local safety monitors.

The trial has been designed in consultation with appropriate regulatory authorities in the European Union, the United States and African countries, in conjunction with the WHO.

Under current plans, the RTS,S vaccine candidate would be submitted to regulatory authorities in 2012 based on efficacy in children 5-17 months of age.

Additional safety and immunogenicity data from the infant population will be submitted soon thereafter, followed by efficacy data for infants once available.

Depending on the final clinical profile of the vaccine and the timetable of the regulatory review process, the first vaccine introduction could take place over the next three to five years.

"GSK's approach is to make every effort possible to accelerate the availability of this life-saving vaccine," said Mr. Jean Stéphenne, President and General Manager, GlaxoSmithKline Biologicals.

"Ever conscious of the burden of malaria, we have no time to lose and we will exhaust every avenue at our disposal. This is our commitment as a company."

久久久无码人妻精品无码_6080YYY午夜理论片中无码_性无码专区_无码人妻品一区二区三区精99

    国产亚洲精品中文字幕| 国产精品久久久久久久久晋中| 久久超碰97中文字幕| 欧美精品一区二区三| 国产精品一区在线| 国产精品夫妻自拍| 欧日韩精品视频| 日本va欧美va精品发布| 久久久久久久久97黄色工厂| 成人激情免费视频| 一区二区三区成人在线视频| 7777精品伊人久久久大香线蕉超级流畅| 免费精品视频最新在线| 国产欧美视频在线观看| 一本久道中文字幕精品亚洲嫩| 偷偷要91色婷婷| 久久综合九色综合欧美亚洲| 成人app网站| 婷婷夜色潮精品综合在线| 亚洲精品一区二区三区蜜桃下载 | 日韩三级免费观看| 国产毛片精品国产一区二区三区| ...av二区三区久久精品| 欧美久久久久久蜜桃| 国产福利一区二区三区| 亚洲一区欧美一区| 欧美xingq一区二区| 91网上在线视频| 蜜臀av性久久久久蜜臀aⅴ流畅| 亚洲国产精品激情在线观看| 欧美色网一区二区| 国产麻豆9l精品三级站| 亚洲男人都懂的| 欧美成人r级一区二区三区| 99久久精品一区二区| 奇米综合一区二区三区精品视频| 中日韩av电影| 91精品欧美综合在线观看最新| 福利电影一区二区| 日韩—二三区免费观看av| 中文字幕欧美激情| 日韩一区二区免费在线观看| 99久久综合精品| 另类小说欧美激情| 亚洲一线二线三线视频| 亚洲国产成人午夜在线一区 | 精品久久久网站| 欧美中文字幕不卡| 国产成人综合亚洲网站| 视频在线在亚洲| 国产精品成人一区二区三区夜夜夜| 91精品国产麻豆国产自产在线| 成人av午夜电影| 精品一区二区三区免费毛片爱| 亚洲国产视频一区二区| 国产精品国产精品国产专区不蜜| 日韩一级片网址| 欧美色综合影院| 91麻豆免费看片| 国产成人在线观看免费网站| 日韩av中文字幕一区二区三区| 亚洲欧美一区二区在线观看| 26uuu欧美| 欧美一区永久视频免费观看| 欧美性色欧美a在线播放| 白白色 亚洲乱淫| 国产福利不卡视频| 麻豆国产精品一区二区三区| 亚洲国产精品久久久男人的天堂| 国产精品家庭影院| 国产午夜一区二区三区| 日韩精品一区二区三区四区 | 蜜桃久久久久久久| 1024精品合集| 国产精品无圣光一区二区| 日韩美女主播在线视频一区二区三区| 欧美网站大全在线观看| 99精品欧美一区二区三区综合在线| 国产精品一区二区三区网站| 麻豆精品一区二区综合av| 午夜影院在线观看欧美| 亚洲夂夂婷婷色拍ww47| 亚洲激情欧美激情| 最新日韩在线视频| www..com久久爱| 国产最新精品免费| 免费视频最近日韩| 石原莉奈在线亚洲二区| 一区二区三区精品视频| 亚洲色欲色欲www在线观看| 国产精品久线观看视频| 亚洲国产精品av| 亚洲国产高清不卡| 国产精品入口麻豆九色| 国产精品区一区二区三区| 久久人人超碰精品| 337p粉嫩大胆噜噜噜噜噜91av | 亚洲国产成人tv| 亚洲黄色免费网站| 一级中文字幕一区二区| 一区二区成人在线观看| 亚洲一二三区视频在线观看| 亚洲激情中文1区| 亚洲国产综合视频在线观看| 亚洲一区在线观看免费 | 在线影院国内精品| 91久久精品网| 欧美日韩在线免费视频| 欧美日韩成人在线| 4438x成人网最大色成网站| 欧美高清视频不卡网| 日韩一级片网站| 26uuu精品一区二区在线观看| 国产亚洲欧美在线| 日本一二三不卡| 亚洲欧美日韩中文字幕一区二区三区 | 欧美日韩精品欧美日韩精品一综合| 在线精品视频小说1| 欧美日韩中文精品| 欧美老女人第四色| 欧美一区二区免费视频| 久久中文字幕电影| 日本一区二区三区久久久久久久久不| 国产精品视频一二三| 一区二区三区四区在线播放| 亚洲国产综合视频在线观看| 日本欧美肥老太交大片| 国产一二三精品| 99国产一区二区三精品乱码| 欧美在线视频你懂得| 69堂精品视频| 久久久精品一品道一区| 亚洲欧洲三级电影| 亚洲chinese男男1069| 老司机一区二区| 成人午夜视频在线观看| 日本精品一区二区三区四区的功能| 欧美日韩亚洲国产综合| 精品国产一区二区三区四区四| 中文字幕电影一区| 亚洲一区二区三区四区在线免费观看| 日韩精品福利网| 国产精品主播直播| 色综合天天综合| 欧美一区日韩一区| 欧美国产日产图区| 午夜精品福利在线| 国产成人在线看| 欧美在线不卡一区| 久久夜色精品国产噜噜av | 亚洲一区二区偷拍精品| 美女免费视频一区二区| fc2成人免费人成在线观看播放| 欧美日韩日日骚| 国产色综合一区| 亚洲国产成人av网| 国产精品18久久久| 欧美日韩成人综合天天影院 | 秋霞影院一区二区| 成人av电影在线播放| 日韩一卡二卡三卡| 亚洲视频你懂的| 精彩视频一区二区| 欧美天堂亚洲电影院在线播放| 久久蜜桃av一区二区天堂| 亚洲一区二区综合| 国产不卡在线视频| 欧美精品黑人性xxxx| 中文字幕一区二区在线观看 | 久久草av在线| 91久久人澡人人添人人爽欧美| 精品美女一区二区| 亚洲国产精品精华液网站| 福利电影一区二区| 日韩欧美成人激情| 亚洲精品网站在线观看| 国产麻豆91精品| 7777精品伊人久久久大香线蕉经典版下载| 日本一区二区视频在线观看| 青青青爽久久午夜综合久久午夜| 99精品久久免费看蜜臀剧情介绍| 欧美成人伊人久久综合网| 亚洲尤物视频在线| 成人av网址在线观看| 精品国产露脸精彩对白 | 亚洲一区在线观看免费观看电影高清| 国产精品资源在线看| 欧美一区日本一区韩国一区| 一级女性全黄久久生活片免费| 国产.精品.日韩.另类.中文.在线.播放| 欧美精品日韩综合在线| 一区二区三区四区蜜桃| 高清av一区二区| 精品久久五月天| 天堂一区二区在线| 日本电影亚洲天堂一区| 国产精品不卡在线| 国产伦理精品不卡| 欧美电影精品一区二区| 亚州成人在线电影|